Save Product
Product Details
Synonyms
CD70, CD27LG, TNFSF7, TNFSF7G, CD27L
Source
Human CD27 Ligand, Llama IgG2b Fc Tag (CDL-H5255) is expressed from human 293 cells (HEK293). It contains AA Ser 52 - Pro 193 (Accession # NP_001243.1).
Predicted N-terminus: Glu
Molecular Characterization
This protein carries a llama IgG2b Fc tag at the N-terminus.
The protein has a calculated MW of 75.5 kDa. The protein migrates as 140-160 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human CD27 Ligand, Llama IgG2b Fc Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) at 2 μg/mL (100 μL/well) can bind Human CD27, His Tag (Cat. No. CD7-H522b) with a linear range of 4-63 ng/mL (QC tested).
Protocol
Immobilized Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD27, Fc,Avitag (Cat. No. TN7-H82F6) with a linear range of 0.3-20 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
CD70 antigen
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
37 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
